Introduction
Proper evaluation of the patient with ac ute c hest pain is a resourc e-intensive and expensive proc ess. Critic al to the effec tive management of these patients are the early rec ognition of a c ardiac isc haemic event and the proper plac ement of the patient in the risk spec trum of the ac ute c oronary syndrome. With inc reasing ec onomic pressures on health c are, physic ians, health plans, and medic al c entres are interested in improving the effic ienc y of c are for patients with ac ute c hest pain. This interest rec ently reinforc ed the need for a better diagnostic approac h to patients with suspec ted ac ute c oronary syndrome and, c onsequently, the need for a new standard definition of ac ute myoc ardial infarc tion ( AMI) and of risk determination.
For muc h of the past three dec ades, ac ute isc haemic heart disease has been regarded as a binary phenomenon, AMI or non-AMI, using World Health Organization rec ommendations that inc luded fulfilment of at least two of the three well-known diagnostic c riteria: a history of ac ute, severe, and prolonged c hest pain; presenc e of signific ant c hanges in elec troc ardiogram ( ECG) ; and unequivoc al abnormal elevation of traditional enzyme ac tivities in serum. Chest pain is, however, an unreliable indic ator: up to 3 3 % of patients with AMI may have no c hest pain and are c linic ally silent on presentation to the hospital. The ECG remains the c ornerstone for the early diagnosis of ac ute isc hemia, showing in approximately 6 0 % of patients STsegment c hange within sec onds of the isc hemic insult. However, the ECG c an be inc onc lusive in the remaining 4 0 % of c ases, therefore showing a globally low sensitivity. The imperfec t sensitivity and spec ific ity of the traditional enzymatic markers for the detec tion of myoc ardial injury is also well known.
In this historic al c ontext, the risk of misdiagnosis was therefore relatively high. Several studies estimated that 2 to 8 % of patients with AMI were inadvertently sent home from emergenc y departments bec ause of the diagnostic limitations of the ECG and of measurements of c lassic enzymes. Inappropriate early disc harge also resulted in signific antly higher morbidity and mortality.
Approaching a new standard for diagnosis
Considering these pitfalls in the traditional c riteria for diagnosis of AMI and the exc ellent findings of several c linic al trials using highly sensitive and spec ific markers of heart musc le damage that are not themselves enzymes, suc h as c ardiac troponins, the Committee on Standardization of Markers of Cardiac Damage ( C-SMCD) of the International Federation of Clinic al Chemistry and Laboratory Medic ine ( IFCC) made a rec ommendation in 1 9 9 9 to expand on the enzyme diagnostic c riteria for AMI to inc lude c ardiac -spec ific proteins. However, the C-SMCD c onsidered that it was the responsibility of c ardiology groups, and not laboratorians, to offic ially redefine the bioc hemic al c riterion for diagnosis of AMI. The c onsensus doc ument published in 2 0 0 0 by the European Soc iety of Cardiology and the Americ an College of Cardiology is therefore the appropriate next step, making spec ific new rec ommendations on the use of biomarkers for the detec tion of myoc ardial nec rosis. In partic ular, the doc ument c onsiders as the best bioc hemic al indic ator for detec ting myoc ardial nec rosis "a c onc entration of c ardiac troponin exc eeding the dec ision limit on at least one oc c asion during the first 2 4 hours after the onset of c linic al event". The use of c reatine kinase MB ( CK-MB) , measured by mass assays, is still c onsidered as an ac c eptable alternative only if c ardiac troponin assays are not available,. The redefined c riterion used to c lassify ac ute c oronary syndrome patients presenting with isc haemic symptoms as AMI patients is therefore heavily predic ated on an inc reased c ardiac troponin c onc entration in blood.
Cardiac troponins are c orrec tly regarded as the most c ardiac -spec ific of c urrently available bioc hemic al markers for the diagnosis of myoc ardial injury. In partic ular, c ardiac troponin I ( c TnI) and c ardiac troponin T ( c TnT) have been identified. These proteins are assoc iated with spec ific amino ac id sequenc es enc oded by genes different from those enc oding skeletal musc le isoforms. The c umulative data indic ate that troponins appear in the serum relatively early after AMI onset ( 4 to 1 0 hours) , peak at 1 2 to 4 8 hours, and remain abnormal for 4 to 1 0 days. These release kinetic s c an be ac c ounted for by examining the distribution of the proteins within the myoc ardial c ell. The great majority of both c TnI and c TnT is bound to the myofibril ( 9 4 to 9 7 %) and a relatively small amount ( approximately 3 % for c TnI and 6 % for c TnT, respec tively) is free in the c ytoplasm. After a c ardiac c ell is injured and the free c ytoplasmic pool is immedi-ately released, there is slow c ontinuous release of the proteins bound to myofibrils, resulting in the observed prolonged troponin elevations noted before. It should be remembered that c ardiac troponins reflec t myoc ardial damage but do not indic ate its mec hanism. Thus, an elevated value in the absenc e of c linic al evidenc e of isc hemic heart disease should prompt a searc h for situations in whic h various degrees of myoc ardial injury may be present ( Table 1 ) . These deserve inc reased attention for two important reasons: these injuries are frequent in c linic al prac tic e, and a signific ant relationship often is shown between c ardiac troponin values and disease severity.
Cardiac troponins should therefore replac e CK-MB testing as the diagnostic "gold standard" for myoc ardial nec rosis. Some c ardiologists however express c onc erns about totally replac ing CK-MB. Many physic ians use the peak serum c onc entration of this isoenzyme to qualitatively estimate infarc t size. Others have questioned the use of serial troponin measurements for monitoring reinfarc tion ( bec ause of the prolonged release pattern) and suggest a c ontinuing role for CK-MB for this purpose. With regard to the first point, it was rec ently showed that a single measurement of plasma c TnT c onc entrations performed at the time c orresponding to the slow c ontinuous release after AMI, i.e. ~7 2 hours after onset, c an be used as a c onvenient and c ost-effec tive, noninvasive estimate of infarc t size, revealing a similar reliability as peak CK-MB measurement ( requiring however repetitive sampling) or nuc lear imaging ( too expensive to be routinely used) . If the major c onc ern about totally replac ing CK-MB with c ardiac troponins in hospital institutions is the lac k of evidenc e on the ability of troponins to estimate the infarc t size, these findings may thus support the definitive implementation of c ardiac troponin testing and the replac ement of CK-MB in the laboratory c ardiac panel.
It may also be appropriate to monitor the c ontinuing dec line of CK-MB daily to show an extension of the infarc t. As only ~4 % of AMI patients experienc ed a reinfarc tion during the stay in Coronary Care Unit, the standard monitoring of this marker to obtain this information c ould however not be c ost-effec tive. Anyway, if laboratories have to retain CK-MB for this partic ular use, the rec ommendation is to use the mass assays, whic h have been shown to be c learly superior to ac tivity-based assays ( suc h as immunoinhibition or elec trophoresis) .
T he suggested biochemical strategy
An important point c onc erns the selec tion of the most appropriate strategy for the use of new markers and the suggested sample frequenc y in patients with c hest pain and without ECG evidenc e of AMI at hospital admission. In fac t, the exc itement of new applic ations in the use of biomarkers to improve routine patient c are c an be offset by the anxiety regarding the appropriate selec tion and utilization of c urrently available and new assays.
Two strategies have c ompeted in this area: -
• The first relies on the use of a c ombination of two markers -a rapid rising marker, suc h as myoglobin, and a marker that takes longer to rise but is more spec ific , suc h as c ardiac troponin -to enable detec tion of AMI in patients who present early and late after symptom onset. As demonstrated in a systematic review of literature, myoglobin is c urrently the marker that most effec tively fits the role as an early marker. Myoglobin is detec table in blood as early as 2 to 3 hours after onset. Its c onc entration appears to peak quic kly, reac hing the maximum c onc entration between 6 and 1 2 hours after the onset of symptoms. It then falls to normal c onc entrations over the next 2 4 hours, and is rapidly c leared from the serum by the kidneys. Measurement of myoglobin has the merit of robust sc ientific evidenc e, with more than 3 0 studies rec ently This two-marker strategy is predic ated on the assumption that early diagnosis of AMI will c hange c are by providing the ability to disc harge patients earlier, thus improving flow within the emergenc y department, and by fac ilitating identific ation of patients who may be c andidates for aggressive interventions and, more in general, fac ilitating the triage of patients who are admitted to various parts of the hospital. Various papers c learly doc ument the high performanc e of the two-marker approac h, showing that the c ombination of myoglobin and troponin signific antly improves the c linic al predic tive values of standard CK-MB alone. In an experienc e in the use of the two-marker protoc ol for diagnosis of c hest pain, the perc entage of ac ute c oronary syndrome-negative patients disc harged in less than one day rose from 2 8 % in the c ontrol group using traditional enzymatic approac h to 5 0 % in the group evaluated by the two-marker protoc ol. Patients disc harged in less than half a day also rose from 2 2 % in the c ontrol group to 3 7 % in the test group. The diagnostic information provided by the two-marker strategy signific antly improved the ac c urac y and timeliness of diagnosis of ac ute c oronary syndrome while reduc ing length of stay and patient episode c ost.
• The sec ond strategy suggests that the urgenc y is less c ritic al than suggested by the first strategy. The tac tic involved is simply to measure c ardiac troponin, with the understanding that definitive exc lusion or inc lusion of AMI will take longer. The logic of this strategy insists that for those hospitals who do not have an area for rapid ruleout of patients with c hest pain, and therefore patient triage dec isions are not made within the first few hours after hospital admission, the use of an early marker is unnec essary. In this c ase, only measurement of c ardiac troponin is suggested with a sampling frequenc y of admission, 6 and 1 2 hours. Onc e again, if c ompared with the traditional enzymatic approac h, this protoc ol is markedly effec tive in altering patient management by enabling early disc harge of patients, resulting in signific ant c ost savings and inc reasing bed availability without c ompromising patient outc ome.
Coming bac k to the sampling protoc ol for detec tion of AMI using the strategy employing early and late markers, the IFCC C-SMCD rec ommends spec imen c ollec tion at hospital admission, 4 , 8 , and 1 2 hours later ( Table 2 ) . This approac h enables the assoc iation of the high predic tability of myoglobin in exc luding AMI within 4 hours after hospital admission and the diagnostic power of a single positive result for troponin that would trigger a diagnosis of myoc ardial nec rosis, without the need for nec essary c ompleting the sequenc e of blood samples at every time point. The question of whether zero time in the protoc ol should be assigned to the onset of c hest pain or presentation to the hospital is debatable. Patients with large infarc ts tend to have a c lear-c ut start to the symptoms and to present early, but normally these are not the patients in whom there is any doubt about the need for hospital admission. In the patients with no ECG c hanges and possible small myoc ardial damage, the symptoms may have a stuttering start and undergo a waxing-and-waning time-c ourse that mirrors the waxing-andwaning myoc ardial isc hemia. It is not unc ommon for these patients to report multiple episodes of c hest pain over the hours and days prior to hospital admission and, in about 1 5 % of them, an inac c urate estimation of the time interval between onset of symptoms and admission has been shown. The suggestion is therefore that, for routine c linic al prac tic e, blood c ollec tions should be referenc ed relative to the time of presentation to the hospital: the use of the rec ommended early and late marker c ombination will permit infarc t timing in any c ase.
Selection of decision limits for troponin use
One of the most important problems in the prac tic al use of the c ardiac -spec ific troponins is the right definition of dec ision limits. The basic question is: "How muc h nec rosis is needed to make the diagnosis of AMI?" In the purest physiologic sense, the answer is that any detec table nec rosis is an AMI. Consequently, even small elevations of spec ific markers of myoc ardial damage, suc h as c ardiac troponins, should be ac knowledged as indic ative of signific ant injury, reflec ting the inc remental risk assoc iated with inc reasing c onc entrations of the marker, c onsistent with the c ontinuous injury c onc ept of ac ute c oronary syndrome. From a c linic al perspec tive, there is c lear evidenc e that any amount of detec table c ardiac troponin release is assoc iated with an inc reased risk of new adverse c ardiac events. Currently available data demonstrate no threshold below whic h elevations of troponin are harmless and without negative implic ations for prognosis. The 'Fragmin During Instability in Coronary Artery Disease' ( FRISC) study, performed in 1 9 9 6 , already showed the c ontinuous relation between c TnT c onc entrations and the risk of c linic al events. More rec ently, the FRISC-II study c onfirmed that optimal risk stratific ation in patients with ac ute c oronary syndrome c an be ac hieved with use of a c ut-off c onc entration around the detec tion limit of the c TnT assay ( i.e., 0 .0 3 mg/L) instead of the manufac turers' suggested higher c ut-off ( i.e., 0 .1 0 mg/L) . Similar results were originally demonstrated for c TnI in the 'Thrombolysis in Myoc ardial Infarc tion' ( TIMI) -IIIB trial and, more rec ently, c onfirmed in TIMI-1 1 B substudy, where use of the upper referenc e limit c onc entrations produc ed signific ant odds ratios with the three c TnI assays employed.
On the basis of all these evidenc es, the c ardiologists' c onsensus doc ument quoted before now defines myoc ardial nec rosis as an inc rease of c ardiac troponin values exc eeding the upper limit of the normal healthy population, set at the 9 9 th perc entile of value distribution to limit the number of false-positive designations of myoc ardial injury. Pragmatic ally,
Sample frequency Marker
Admission +4 h +8 h +12 h or next morning the use of this approac h as a diagnostic c riterion for AMI will lead to an inc rease in the numbers of infarc t patients in the ac ute c oronary syndrome population from 1 5 to 3 0 %. However, the doc ument emphasizes that in applying the proposed new diagnostic c riteria to c linic al prac tic e, patients should not be labeled simply as "myoc ardial infarc tion", but rather as patients with c oronary artery disease in whom the extent of myoc ardial nec rosis should be c learly defined as mic rosc opic , small, medium or large and possibly related to the c urrent left ventric ular func tion. On the other hand, inc reasing diagnostic sensitivity for AMI c an have a positive impac t on soc iety, resulting in more c ases being identified, thereby allowing appropriate sec ondary prevention and hopefully reduc ing health c are c osts in the future. In a rec ent study, patients who had an AMI diagnosis made solely on the basis of a positive troponin value experienc ed a 3 -fold inc rease in short-term mortality c ompared with the normal troponin group.
Ac c ording to the suggestions of the c ardiologists' doc ument, the diagnostic manufac turers must now provide on the pac kage insert sheet of kits the 9 9 th referenc e limit of the spec ific troponin assays, based on informations available from peer-reviewed literature and obtained using the IFCC rec ommendations on the theory of referenc e values, published in a series of artic les during 1 9 8 7 .
Lac king between-assay standardization, referenc e limits need, of c ourse, to be determined separately for eac h assay and platform, even if available from the same manufacturer. This information should be available along with the level of analytic al imprec ision of the assay at this c onc entration limit. Ac c urate disc rimination between "minor" myoc ardial injury vs analytic al noise requires assays that have high prec ision at low troponin c onc entrations. For c linic al use, the IFCC C-SMCD rec ommends for troponin assays a total imprec ision, expressed as c oeffic ient of variation ( CV) , of < 1 0 % at the AMI dec ision limit. A failure to reac h this goal c ould inc rease the risk of reporting misleading results that will either prompt unnec essary c onfirmatory testing, as in the c ase of artifac tually abnormal c onc entrations, or lead to c linic al inac tion when inappropriately low c onc entrations are reported for patients. This plac es a large responsibility on the manufac turers of troponin assays to ensure that their assays have the nec essary prec ision to permit the use of the proposed c ut-off, i.e. the 9 9 th perc entile limit of the referenc e population. At present, and from this point of view, not all the troponin assays perform equally well in routine c linic al settings, and many c ommerc ially available assays c annot indeed meet the 1 0 % CV rec ommendation at the 9 9 th perc entile values. Clinic al laboratories should therefore c onsider more c arefully the effec t of imprec ision on c linic al dec ision making when they implement an assay for troponin determination.
On the other hand, manufac turing industries should c arefully c onsider this c ritic al issue bec ause diagnostic and therapeutic dec isions will onwards be based on lower c ardiac troponin c ut points. Table 3 is plac ed at the end of this c hapter .
perc entile value, a predetermined higher c onc entration that meets this imprec ision goal should be used as c ut-off for AMI until the goal of a 1 0 % CV c an be ac hieved at the 9 9 th perc entile ( Table 3 ) . Of c ourse, this c ould however dec rease the overall c linic al sensitivity of the assay.
Conclusion
New bioc hemic al markers are integral to the diagnosis and management of patients in whom ac ute c oronary syndrome is suspec ted. The role of bioc hemic al testing as a part of a struc tured dec ision-making protoc ol is to provide ac c urate and timely information that c an be used to guide patient management. In this respec t, the diagnostic superiority of the new markers of myoc ardial damage opens fasc inating perspec tives for the triage and management of patients with ac ute myoc ardial isc hemia.
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